导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.72% | 2011/4773 |
| 近一周 | -1.85% | 3005/5465 |
| 近一月 | -1.39% | 1134/5421 |
| 近一季 | -3.58% | 1644/5231 |
| 近半年 | -2.54% | 2182/4920 |
| 近一年 | 3.48% | 2070/4394 |
| 近两年 | 50.06% | 1495/2954 |
| 近三年 | 34.25% | 932/2253 |
| 成立以来 | 147.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.34% 2243/4961 |
7.89% 2651/5312 |
- - |
- - |
| 2025 | 17.62% 2364/4813 |
-1.83% 2789/3635 |
5.07% 654/4076 |
13.78% 2967/4524 |
0.23% 2116/4813 |
| 2024 | 20.76% 442/3463 |
4.27% 466/2808 |
-0.68% 818/3014 |
14.63% 1940/3129 |
1.74% 1038/3463 |
| 2023 | -4.68% 689/2656 |
6.68% 659/2280 |
-1.40% 481/2385 |
-2.82% 755/2515 |
-6.75% 1903/2655 |
| 2022 | -14.76% 391/2207 |
-10.79% 426/1919 |
4.56% 1000/2016 |
-10.69% 439/2113 |
2.32% 972/2208 |
| 2021 | 9.58% 454/1822 |
-1.19% 447/1255 |
6.75% 724/1330 |
3.35% 410/1466 |
0.51% 1098/1822 |
| 2020 | 33.86% 448/1250 |
-6.54% 495/1028 |
10.66% 759/1067 |
15.44% 214/1164 |
12.11% 501/1184 |
| 2019 | 27.62% 539/1092 |
25.92% 436/754 |
-2.71% 360/804 |
-1.54% 663/850 |
5.80% 672/918 |
| 2018 | -20.17% 188/834 |
- - |
- - |
- - |
-9.89% 167/691 |
| 2017 | 13.60% 261/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.47% 303/605 |
- - |
- - |
- - |
- - |
| 2015 | 11.45% 158/575 |
- - |
- - |
- - |
- - |
| 2014 | 50.46% 83/237 |
- - |
- - |
- - |
- - |
| 2013 | 3.19% 61/186 |
- - |
- - |
- - |
- - |
| 2012 | 3.56% 89/140 |
- - |
- - |
- - |
- - |
| 2011 | -29.73% 90/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 易方达上证中盘ETF联接A VS. 长安沪深300非周期A(740101) |